02.08.24
Palmitoylethanolamide (PEA), a fatty acid amide found naturally in some foods, may be helpful in reducing the severity and duration of migraines, according to a new human clinical trial published in Pharmaceuticals.
In the double-blind, placebo-controlled study, 64 participants were instructed to take 600 mg of Gencor’s PEA ingredient, Levagen+, every time they had a migraine, and over the duration of the study, 155 migraines were reported.
Once the dose was taken, participants recorded a visual analog scale (VAS) for pain every 30 minutes for four hours or until the migraine resolved. If the migraine had not resolved two hours post-dose, participants were instructed to take another supplement.
There was no significant difference between the number of migraines recorded per group, reported migraine severity at onset, or rescue medication use within the first four hours. However, compared to placebo, Levagen+ resolved more migraines at two and eight hours. Levagen+ participants also had a lower VAS for pain score at one-and-a-half and four hours and significantly reduced rescue medication use compared to placebo.
“Palmitoylethanolamide has a long history in the scientific literature for its management of clinical conditions due to its reported analgesic and anti-inflammatory effects. In the context of the current study on migraine pain, PEA is proposed to modulate pain by interacting with the endocannabinoid system and reducing inflammation,” the authors concluded, noting that the present study is in line with prior research on the relationship between PEA and migraines.
“The results of this study further back PEA’s clinically validated benefits for its analgesic and inflammatory properties in addition to its neuroprotective effects,” said R.V. Venkatesh, co-founder and managing director at Gencor. “We are thrilled about the promising results and potential of Levagen+ to support those who suffer from migraine.”
Levagen+ utilizes LipiSperse, a delivery technology which makes hydrophobic ingredients capable of dispersion into water, in turn making it more bioavailable.
In the double-blind, placebo-controlled study, 64 participants were instructed to take 600 mg of Gencor’s PEA ingredient, Levagen+, every time they had a migraine, and over the duration of the study, 155 migraines were reported.
Once the dose was taken, participants recorded a visual analog scale (VAS) for pain every 30 minutes for four hours or until the migraine resolved. If the migraine had not resolved two hours post-dose, participants were instructed to take another supplement.
There was no significant difference between the number of migraines recorded per group, reported migraine severity at onset, or rescue medication use within the first four hours. However, compared to placebo, Levagen+ resolved more migraines at two and eight hours. Levagen+ participants also had a lower VAS for pain score at one-and-a-half and four hours and significantly reduced rescue medication use compared to placebo.
“Palmitoylethanolamide has a long history in the scientific literature for its management of clinical conditions due to its reported analgesic and anti-inflammatory effects. In the context of the current study on migraine pain, PEA is proposed to modulate pain by interacting with the endocannabinoid system and reducing inflammation,” the authors concluded, noting that the present study is in line with prior research on the relationship between PEA and migraines.
“The results of this study further back PEA’s clinically validated benefits for its analgesic and inflammatory properties in addition to its neuroprotective effects,” said R.V. Venkatesh, co-founder and managing director at Gencor. “We are thrilled about the promising results and potential of Levagen+ to support those who suffer from migraine.”
Levagen+ utilizes LipiSperse, a delivery technology which makes hydrophobic ingredients capable of dispersion into water, in turn making it more bioavailable.
